Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemotherapy in neoadjuvant gastric cancer
NCT05545436Phase 2Unknown
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2022
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab in gastric cancer (GC) and gastroesophageal junction cancer, sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05545436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05545436.